The Australian Cardio-Oncology Registry (ACOR) is a prospective national cardio-oncology registry in paediatrics, adolescent and young adult (AYA) cancer patients and survivors. ACOR is coordinated by Murdoch Children’s Research Institution and is supported by a national partnership of 11hospitals and research institutions.
ACOR aims to provide a research platform from which longitudinal data can be attained and through which further research can be developed to better provide outcomes for children and young adults who are at risk of cancer therapy related cardiovascular dysfunction (CRTCD). ACOR will achieve this through the establishment of:
- A registry of all paediatric and AYA patients who have been exposed to cardiac toxic chemotherapy
- MBS/PBS data linkage which will allow for an accurate reflection of patient use of the health care system in the outpatient setting when they develop CTRCD in comparison to those who do not develop heart toxicity
- A biobanking study whose purpose will be to determine if genetic variants in cardiac health genes predispose patients to CTRCD
- Extended Cardiac Evaluation study to assess whether the use of the adult gold standard (cardiac magnetic resonance imaging) will result in better detection and management of heart toxicity in children with cancer.
ACOR’s unique cohort will provide data that will enable researchers to address deficiencies which is necessary in order to improve the health outcomes for the estimated 300,000 children, and their families, who are exposed each year to the cardiac insult of cancer therapy. ACOR will achieve these aims through meaningful collaborations between clinical specialties of cardiology and oncology, a national partnership of 11 hospitals and research institutions, research and education and advocacy.